Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2016’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma)

The report reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics and enlists all their major and minor projects

The report assesses Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biofrontera AG

Biosceptre (Aust) Pty Ltd

Cannabis Science, Inc

Genextra S.p.a.

Ignyta, Inc.

Laboratories Ojer Pharma S.L.

MediGene AG

Merck & Co., Inc.

PellePharm, Inc.

Provectus Biopharmaceuticals, Inc.

Redx Pharma Plc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Transgene SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 7

Therapeutics Development 8

Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview 8

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies 9

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies 13

Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development 14

Biofrontera AG 14

Biosceptre (Aust) Pty Ltd 15

Cannabis Science, Inc 16

Genextra S.p.a. 17

Ignyta, Inc. 18

Laboratories Ojer Pharma S.L. 19

MediGene AG 20

Merck & Co., Inc. 21

PellePharm, Inc. 22

Provectus Biopharmaceuticals, Inc. 23

Redx Pharma Plc 24

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 25

Transgene SA 26

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

aminolevulinic acid hydrochloride - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

aminolevulinic acid hydrochloride - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

BIL-010t - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

BLR-300 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

CS-S/BCC-1 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

CSTATI-1 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

DAC-060 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

imiquimod SR - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Oshadi D + Oshadi R - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

patidegib hydrochloride - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

pembrolizumab - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

PV-10 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

RDX-001 - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

sinecatechins - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

taladegib - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

TG-1042 - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects 106

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products 107

Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones 108

Featured News & Press Releases 108

Jul 28, 2016: Biofrontera Receives Favourable CHMP Assessment for Field-Directed Therapy and Files BCC Application 108

Jun 23, 2016: Biofrontera Progresses with Expansion of U.S. Subsidiary with Key Personnel Hires 108

Nov 19, 2015: Biofrontera reports final patient visit in phase III trial for basal cell carcinoma 109

Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 109

Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma 110

Appendix 111

Methodology 111

Coverage 111

Secondary Research 111

Primary Research 111

Expert Panel Validation 111

Contact Us 111

Disclaimer 112

List of Tables

List of Tables

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Biofrontera AG, H2 2016 14

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Biosceptre (Aust) Pty Ltd, H2 2016 15

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Cannabis Science, Inc, H2 2016 16

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Genextra S.p.a., H2 2016 17

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Ignyta, Inc., H2 2016 18

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Laboratories Ojer Pharma S.L., H2 2016 19

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by MediGene AG, H2 2016 20

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Merck & Co., Inc., H2 2016 21

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by PellePharm, Inc., H2 2016 22

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 23

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Redx Pharma Plc, H2 2016 24

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016 25

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Transgene SA, H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Assessment by Combination Products, H2 2016 28

Number of Products by Stage and Target, H2 2016 30

Number of Products by Stage and Mechanism of Action, H2 2016 32

Number of Products by Stage and Route of Administration, H2 2016 34

Number of Products by Stage and Molecule Type, H2 2016 36

Basal Cell Carcinoma (Basal Cell Epithelioma) – Dormant Projects, H2 2016 106

Basal Cell Carcinoma (Basal Cell Epithelioma) – Discontinued Products, H2 2016 107

List of Figures

List of Figures

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Targets, H2 2016 29

Number of Products by Stage and Targets, H2 2016 29

Number of Products by Mechanism of Actions, H2 2016 31

Number of Products by Stage and Mechanism of Actions, H2 2016 31

Number of Products by Routes of Administration, H2 2016 33

Number of Products by Stage and Routes of Administration, H2 2016 33

Number of Products by Molecule Types, H2 2016 35

Number of Products by Stage and Molecule Types, H2 2016 35

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports